Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Affiliations

• ¹ Division of Infection, Barts Healthcare NHS Trust, London, UK These authors contributed equally to this work.
• ² Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy These authors contributed equally to this work.
• ³ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy Public Health Consulting Group, Lugano, Switzerland These authors contributed equally to this work.
• ⁴ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy These authors contributed equally to this work.
• ⁵ University Center of Araraquara, Sao Paulo, Brazil Hospital Nestor Goulart Reis, Sao Paulo State Secretary of Health, Sao Paulo, Brazil.
• ⁶ International Union against Tuberculosis and Lung Disease (The Union), Lima, Peru MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, France.
• ⁷ University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
• ⁸ MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, France Pneumology Dept, Hospital General de Gran Canaria "Dr. Negrin", Las Palmas de Gran Canaria, Spain.
• ⁹ MDR-TB Unit, Athens Chest Hospital Sotira, National Referral Centre for Mycobacteria, Athens, Greece.
• ¹⁰ Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.
• ¹¹ Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
• ¹² National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Catholic University Ruzomberok, Ruzomberok, Slovakia.
• ¹³ University Dept of Infectious and Tropical Diseases, WHO Collaborating Centre for TB/HIV Co-infection and for TB Elimination - University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy.
• ¹⁴ Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
• ¹⁵ National Tuberculosis Control Programme, Ministry of Health, Lima, Peru.
• ¹⁶ AOVV E. Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy.
• ¹⁷ National Tuberculosis Control Programme, Pulmonology Hospital Alfredo J. Valenzuela, Guayaquil, Ecuador.
• ¹⁸ MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease (The Union), Paris, France.
• ¹⁹ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis; TB Center Beatrixoord, Groningen, The Netherlands.
• ²⁰ Educational Institution "Grodno State Medical University", Grodno, Belarus.
• ²¹ KNCV Tuberculosis Foundation, The Hague, The Netherlands.
• ²² Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy.
• ²³ Dept of Respiratory Medicine, Queen Mary University, London, UK.
• ²⁴ Division of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
• ²⁵ Pneumology Unit, Fondazione Maugeri, IRCCS, Tradate, Italy Dept of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.
• ²⁶ National Hospital Hipólito Unanue, Public Health Institute, Ministry of Health, Lima, Peru.
• ²⁷ Dept of Respiratory Medicine, Barts Healthcare NHS Trust, London, UK.
• ²⁸ Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.
• ²⁹ WHO Collaborating Centre for TB and Lung Diseases, Fondazione S. Maugeri, Tradate, Italy [email protected].